Asterias Biotherapeutics Stock Beta
Asterias Biotherapeutics fundamentals help investors to digest information that contributes to Asterias Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Asterias Stock. The fundamental analysis module provides a way to measure Asterias Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Asterias Biotherapeutics stock.
Asterias |
Asterias Biotherapeutics Company Beta Analysis
Asterias Biotherapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Asterias Biotherapeutics Beta | 3.73 |
Most of Asterias Biotherapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Asterias Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Asterias Biotherapeutics has a Beta of 3.73. This is 333.72% higher than that of the sector and 168.35% higher than that of the Beta industry. The beta for all United States stocks is notably lower than that of the firm.
Asterias Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Asterias Biotherapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Asterias Biotherapeutics could also be used in its relative valuation, which is a method of valuing Asterias Biotherapeutics by comparing valuation metrics of similar companies.Asterias Biotherapeutics is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Asterias Biotherapeutics will likely underperform.
Asterias Fundamentals
| Return On Equity | -93.17 | |||
| Return On Asset | -0.68 | |||
| Profit Margin | (4.60) % | |||
| Current Valuation | 40.31 M | |||
| Shares Outstanding | 55.66 M | |||
| Shares Owned By Insiders | 40.33 % | |||
| Shares Owned By Institutions | 13.75 % | |||
| Number Of Shares Shorted | 409.74 K | |||
| Price To Earning | (3.41) X | |||
| Price To Book | 2.02 X | |||
| Price To Sales | 67.77 X | |||
| Revenue | 731 K | |||
| Gross Profit | 3.88 M | |||
| EBITDA | (41.26 M) | |||
| Net Income | (20.3 M) | |||
| Cash And Equivalents | 12.59 M | |||
| Cash Per Share | (0.61) X | |||
| Total Debt | 16 K | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 6.50 X | |||
| Book Value Per Share | 1.16 X | |||
| Cash Flow From Operations | (15.82 M) | |||
| Short Ratio | 2.31 X | |||
| Earnings Per Share | (0.37) X | |||
| Number Of Employees | 31 | |||
| Beta | 3.73 | |||
| Market Capitalization | 52.6 M | |||
| Total Asset | 66.98 M | |||
| Retained Earnings | (59.85 M) | |||
| Working Capital | 19.54 M | |||
| Current Asset | 29.79 M | |||
| Current Liabilities | 10.25 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Asterias Stock
If you are still planning to invest in Asterias Biotherapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Asterias Biotherapeutics' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |